Patents Assigned to Sanford Burnham Prebys Medical Discovery Institute
-
Patent number: 11447453Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.Type: GrantFiled: March 12, 2020Date of Patent: September 20, 2022Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Nicholas David Peter Cosford, Dhanya Raveendra-Panickar, Douglas J. Sheffler, John Howard Hutchinson, Reto Andreas Gadient
-
Patent number: 11376303Abstract: Disclosed are methods and compositions for treating traumatic brain injury (TBI). A brain injury-specific 4-amino acid peptide (sequence CAQK), identified by in vivo phage display screening in mice with acute brain injury, shows selective binding to mouse and human brain injury lesions, and when systemically injected, specifically homes to sites of injury in penetrating and non-penetrating (controlled cortical impact) brain injury models. Significantly, the peptide alone produces therapeutic effect and so can be used in the absence of any other therapeutic compound.Type: GrantFiled: December 6, 2018Date of Patent: July 5, 2022Assignee: Sanford Burnham Prebys Medical Discovery InstituteInventors: Erkki Ruoslahti, Sazid Hussain, Aman Preet Singh Mann, Pablo Scodeller
-
Patent number: 11365221Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.Type: GrantFiled: June 8, 2020Date of Patent: June 21, 2022Assignee: Sanford Burnham Prebys Medical Discovery InstituteInventors: Carl Ware, John Sedy
-
Patent number: 11352428Abstract: The present invention relates to the seminal discovery that BTLA agonist antibodies modulate the immune system. Specifically, the present invention provides antibodies which bind BTLA in the activated state enhancing BTLA signaling. The present invention further provides methods of treating immune and inflammatory diseases and disorders with a BTLA agonist antibody.Type: GrantFiled: April 29, 2016Date of Patent: June 7, 2022Assignee: Sanford Burnham Prebys Medical Discovery InstituteInventors: Carl F. Ware, John Sedy, Paula Norris
-
Patent number: 11345705Abstract: Provided herein are agonists of the apelin receptor of Formula (I): for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.Type: GrantFiled: August 8, 2018Date of Patent: May 31, 2022Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Layton H. Smith, Anthony B. Pinkerton, Paul Hershberger, Patrick Maloney, Danielle McAnally
-
Publication number: 20220143203Abstract: Provided herein are biomolecule conjugates, and methods of use thereof, wherein the conjugate comprises a cytokine, typically an immunopotentiating cytokine, and a peptide comprising or consisting of the sequence CSGRRSSKC (SEQ ID NO:1). Biomolecule conjugates of the invention find application, inter alia, in the treatment of tumours, atherosclerosis and fibrosis, and the degradation of ECM associated therewith. Also provided herein are uses of a peptide comprising or consisting of the sequence of SEQ ID NO:1, optionally linked to a detectable agent and/or a carrier, in the detection and/or localisation of tumour, atherosclerotic and fibrotic tissue.Type: ApplicationFiled: October 26, 2021Publication date: May 12, 2022Applicants: The University of Western Australia, Sanford Burnham Prebys Medical Discovery InstituteInventors: Juliana Binti HAMZAH, Ruth Annelore GANSS, Erkki RUOSLAHTI, Hector R. BILIRAN, JR.
-
Patent number: 11261164Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.Type: GrantFiled: January 14, 2020Date of Patent: March 1, 2022Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
-
Patent number: 11220486Abstract: Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A).Type: GrantFiled: February 18, 2020Date of Patent: January 11, 2022Assignees: LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Nunzio Bottini, Jiwen Zou, Santhi R. Ganji, Stephanie Stanford, Anthony Pinkerton, Thomas D. Y. Chung, Michael Hedrick, Robert Ardecky
-
Publication number: 20210355087Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the following formula (I): wherein X1 represents a nitrogen atom or CR9, R1 represents a hydrogen atom, a C1-C6 alkyl group, or a C1-C6 alkoxy group, R2 represents a halogen atom, R3 represents a hydrogen atom or a halogen atom, R4 represents a hydrogen atom or a halogen atom, and R5 represents a C1-C3 alkylsulfonyl group, a substituted C1-C6 alkyl group, a substituted C1-C6 haloalkyl group, a substituted C1-C6 alkoxy group, or a substituted C1-C6 alkylamino group, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: October 22, 2019Publication date: November 18, 2021Applicants: DAIICHI SANKYO COMPANY, LIMITED, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Takashi Tsuji, Yasunobu Kurosaki, Koutaro Ishibashi, Anthony B. Pinkerton
-
Patent number: 11155525Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.Type: GrantFiled: April 20, 2020Date of Patent: October 26, 2021Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Takuya Ikeda, Yoshiyuki Kobayashi, Naoki Miyoshi, Osamu Suzuki, Takahiro Nagayama, Takashi Tsuji, Layton H. Smith, Anthony B. Pinkerton
-
Publication number: 20210300882Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.Type: ApplicationFiled: June 8, 2021Publication date: September 30, 2021Applicant: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
-
Patent number: 11111270Abstract: Provided herein are compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.Type: GrantFiled: January 10, 2020Date of Patent: September 7, 2021Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Nicholas David Peter Cosford, Mitchell Dennis Vamos
-
Publication number: 20210228733Abstract: Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.Type: ApplicationFiled: April 12, 2021Publication date: July 29, 2021Applicants: University of Central Florida Research Foundation, Inc., Sanford Burnham Prebys Medical Discovery Institute at Lake Nona, Memorial Sloan Kettering Cancer CenterInventors: Annette Khaled, Jesus Manuel Perez Figueroa, Santimukul Santra, Charalambos Kaittanis, Oscar Santiesteban, Jan Grimm, Hampton Sessions
-
Patent number: 11066420Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.Type: GrantFiled: April 27, 2018Date of Patent: July 20, 2021Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Anthony B. Pinkerton, Robert J. Ardecky, Jiwen Zou
-
Patent number: 11046710Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: December 22, 2017Date of Patent: June 29, 2021Assignees: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery InstituteInventors: Shojiro Miyazaki, Masaharu Inui, Yasunobu Kurosaki, Yuko Yamamoto, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Masamichi Kishida
-
Publication number: 20210188909Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).Type: ApplicationFiled: June 1, 2020Publication date: June 24, 2021Applicant: Sanford Burnham Prebys Medical Discovery InstituteInventors: Tambet Teesalu, Erkki Ruoslahti, Kazuki Sugahara, Shweta Sharma
-
Patent number: 11028061Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.Type: GrantFiled: July 27, 2016Date of Patent: June 8, 2021Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
-
Patent number: 11014939Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.Type: GrantFiled: December 22, 2017Date of Patent: May 25, 2021Assignees: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery InstituteInventors: Shojiro Miyazaki, Masaharu Inui, Yasunobu Kurosaki, Yuko Yamamoto, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Masamichi Kishida
-
Patent number: 11007303Abstract: An implant is provided comprising a substrate having one or more nanoceria coatings coated at least partially thereon, wherein the one or more nanoceria coatings comprise surface cerium having a 3+/4+ oxidation state ratio such that the one or more nanoceria coatings exhibit catalase mimetic activity, superoxide dismutase mimetic activity, or both. Methods are provided for forming a nanoceria coaling. The coating has nanoceria having a surface cerium 3+/4+ oxidation state ratio such that such that the coating exhibits catalase mimetic activity, superoxide dismutase mimetic activity, or both. Also disclosed is a method of reducing degradation of an implant by placing nanoceria in proximity to a bone-implant interface.Type: GrantFiled: October 6, 2016Date of Patent: May 18, 2021Assignees: University of Central Florida Research Foundation, Inc., Sanford Burnham Prebys Medical Discovery InstituteInventors: Sudipta Seal, Soumen Das, William Self, Dwight Towler
-
Patent number: 11008325Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.Type: GrantFiled: November 14, 2017Date of Patent: May 18, 2021Assignees: VIRGINIA COMMONWEALTH UNIVERSITY, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Paul B. Fisher, Maurizio Pellecchia, Swadesh K. Das, Timothy P. Kegelman, Bainan Wu, Surya K. De, Jun Wei, Mitchell E. Menezes, Luni Emdad